Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5447010 | 0.90 | KMT2A (0.39) | KMT2AF2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL5457234 | 0.84 | MAPK14 (0.39) | KMT2AF2AURKASMN1; SMN2NPC1 | |
| SCHEMBL5454345 | 0.84 | AURKA (0.53) | KMT2AF2AURKA | |
| SCHEMBL5449357 | 0.82 | HRH4 (0.41) | KMT2AF2AURKASMN1; SMN2NPC1 | |
| SCHEMBL5448086 | 0.82 | NPC1 (0.43) | KMT2ASMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL5454247 | 0.82 | F2 (0.39) | KMT2AF2AURKASMN1; SMN2NPC1 | |
| SCHEMBL5454354 | 0.82 | SMN1; SMN2 (0.42) | KMT2AF2AURKASMN1; SMN2RAB9A | |
| SCHEMBL5456591 | 0.81 | GAA (0.47) | AURKASMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL5454400 | 0.81 | ACHE (0.39) | KMT2AF2AURKASMN1; SMN2TP53 | |
| SCHEMBL5451776 | 0.80 | GAA (0.36) | KMT2AF2AURKASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-02-15 | — | — | US | claimed |
| EP-1608364-A1 | BICYCLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2005-12-28 | — | — | EP | claimed |
| WO-2004080457-A1 | BICYCLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2004-09-23 | — | — | WO | claimed |
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K15, MAP3K7, MAP3K19 | KMT2A 2155/4885F2 4351/4885AURKA 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.